Log In
Print this Print this

denintuzumab mafodotin (SGN-CD19A) (formerly SGN-19A)

  Manage Alerts
Collapse Summary General Information
Company Seattle Genetics Inc.
DescriptionAntibody-drug conjugate (ADC) composed of an anti-CD19 mAb and monomethyl auristatin F (MMAF)
Molecular Target CD19
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today